CHEK2 variant I157T may be associated with increased breast cancer risk
✍ Scribed by Outi Kilpivaara; Pia Vahteristo; Jacob Falck; Kirsi Syrjäkoski; Hannaleena Eerola; Douglas Easton; Jirina Bartkova; Jiri Lukas; Päivi Heikkilä; Kristiina Aittomäki; Kaija Holli; Carl Blomqvist; Olli-Pekka Kallioniemi; Jiri Bartek; Heli Nevanlinna
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 173 KB
- Volume
- 111
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Cell cycle checkpoint kinase 2 (CHEK2) is a transducer of cellular responses to DNA damage. The CHEK2 1100delC has previously been shown to be a low‐penetrance breast cancer susceptibility allele. We have evaluated the role of another CHEK2 variant, I157T in the FHA domain of the gene, for association with breast cancer. I157T was found at a significantly higher frequency in the population‐based series of breast cancer patients (77/1035, 7.4%, odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.06–1.95, p = 0.021) than among population controls (100/1885, 5.3%). The frequency in the familial breast cancer patients was not elevated (28/507, 5.5%, OR = 1.04, 95% CI = 0.68–1.61). The I157T protein, that undermines cellular responses to ionizing radiation and shows deficiency in substrate recognition in vivo, was expressed at normal level in tumor tissues as well as in cultured cells. The I157T protein was stable and it dimerized with the wild‐type CHEK2 co‐expressed in human cells. These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild‐type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
The association between the CHEK2 and breast cancer risk in Chinese women is unknown. Here, we screened the full CHEK2 coding sequence in 118 Chinese familial breast cancer cases who are negative for mutations in BRCA1 and BRCA2, one recurrent mutation, CHEK2 c.1111C4T (p.H371Y), was identified in f
## Abstract Germline mutations in __CHEK2__ have been associated with a range of cancer types but little is known about disease risks conveyed by __CHEK2__ mutations outside of the context of breast and prostate cancer. To investigate whether __CHEK2__ mutations confer an increased risk of bladder
## Abstract p21^Cip1^ and p27^Kip1^ are cyclin‐dependent kinase inhibitors, which can arrest cell proliferation and serve as tumor suppressors. Reduced protein expression of p21^Cip1^ and p27^Kip1^ was frequently observed in a subset of cancers, including breast cancer. In this study, we hypothesiz